Resources
23 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 1/8/2024 (updated 3/28/2024)
The Neonatal Abstinence Syndrome (NAS) Cohort I tip sheet is a result of collaborative efforts of the NAS Cohort I grant recipients. Drawing on the insights and experiences of our grantees, we identified 9 key recommendations. These tips serve not only as a guiding framework for future NAS cohort grantees but also offers valuable guidance to all RCORP grant cohorts. This resource aims to enhance effectiveness and increase the impact of all RCORP grantee initiatives.
Posted 9/29/2023 (updated 3/27/2024)
The RCORP-TA NAS II Onboarding Packet is a tool to support the implementation of planned activities and to expand SUD/OUD services across the care spectrum thereby helping rural residents in communities to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 7/26/2023 (updated 3/26/2024)
This presentation included an overview of the Moms Do Care EMPOWER (Engaging Mothers for Positive Outcomes with Early Referrals) program at Baystate Franklin Medical Center (BFMC). We discussed our history and program model.
Posted 6/7/2022 (updated 3/27/2024)
Cohort-Specific Sessions/Activities and Day 2 Wrap-Up
Posted 6/6/2022 (updated 3/27/2024)
This session highlighted over a decade of Community Apgar research and its implementation supporting community development for physician recruitment and retention in rural FQHCs and CAHs. This presentation also included ongoing implementation of the program through collaboration with 3RNet and the use of a “Factors Book” which can highlight community assets and focus recruitment efforts to better meet community needs.
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.
Posted 12/22/2021 (updated 3/26/2024)
This guide provides rural health care leaders and teams with foundational knowledge, strategies, and resources to understand the impact of social determinants of health (SDOH) on patients and communities. It organizes key information and resources to help the busy manager support and lead education and discussion with front-line staff. This guide focuses on (1) understanding the need and opportunity around addressing SDOH, (2) using local data to support decision making, and (3) involving team members to plan and implement action steps.
Posted 10/26/2021 (updated 4/3/2024)
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.